Cancers potentially attributable to excess body weight in Aotearoa New Zealand from 2019 to 2023
Michael Walsh1, Jennifer Brenton-Peters2, Olivia Perelini3
1Epidemiologist, Planning, Funding and Outcomes, Health New Zealand - Te Whatu Ora, Auckland, Aotearoa New Zealand.
Aim:
This study quantifies the incidence of cancers attributable to excess body weight (EBW) in Aotearoa New Zealand adults aged 30+ from 2019 to 2023 and assesses public health implications.
Methods:
Relative risk estimates from an existing review and EBW prevalence from the New Zealand Health Survey were used to calculate population attributable fractions (PAFs) for 12 cancer types. PAFs were applied to Cancer Registry data to estimate EBW-attributable cases. Confidence intervals were calculated using bootstrap techniques. Two scenarios explored the potential impact of reducing EBW prevalence.
Results:
An estimated 6,962 cancers (5.1% of all cases) were potentially attributable to EBW, averaging 1,390 cases annually. The impact was greater for females (PAF 6.3%) than males (PAF 4.1%). Among Māori, 6.9% of cancers (221 per year) were attributed to EBW, while Pacific peoples had a higher PAF of 11.8% (145 cases per year). PAFs were highest for Pacific females (16.1%, 110 per year). Modelling suggests halving EBW prevalence could potentially prevent 600 cases annually.
Conclusion:
EBW contributes to a large number of cancers in New Zealand, compounding health inequities, particularly for Māori and Pacific peoples. These inequities highlight the urgent need for multisectoral, collaborative interventions that address the complex, inequitable drivers of EBW. Public health must strengthen its pro-equity, anti-stigmatising approach to prevention, management and treatment. However, sustained reductions in EBW-related cancers will ultimately depend on preventing EBW rather than relying on treatment-based interventions.
Related Concept Videos
Cancer Prevention
Some...
Obesity
Stress Prevention and Stress Management Techniques IV
Cancer Survival Analysis
Psychoneuroimmunology: Diabetes and Cancer
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...


